NASDAQ: RPRX · Health Technology
Which UK funds hold Royalty Pharma plc (RPRX)?
Royalty Pharma plc (RPRX) is among the ten largest holdings of 1 UK fund Fundology covers, according to the holdings each fund publishes. The largest weight is 1.77%, in SBIX (Invesco NASDAQ Biotech UCITS ETF), as of 15/10/2026. In all, 124 funds list it among their published holdings. 13 swap-based funds also list Royalty Pharma plc (RPRX) in the substitute baskets they hold as collateral; they track different indices through swaps and are not counted as holders.
UK funds that hold Royalty Pharma plc
Funds where it is one of the ten largest holdings, largest weight first. A weight is the share of the fund’s money in this company.
| Fund | Weight in the fund | Holdings as of |
|---|---|---|
| SBIX · Invesco NASDAQ Biotech UCITS ETFIE00BQ70R696 | 1.77% |
Source: fund issuers’ published holdings, dates differ by fund
Funds that hold it further down
123 more funds list Royalty Pharma plc below their ten largest holdings.
Create a free account to see every fund that holds this company, at any weight
Sign-up takes an email address. There is no card to enter and nothing to pay.
About Royalty Pharma plc
Royalty Pharma plc is listed on NASDAQ under the symbol RPRX, in the health technology sector as TradingView classifies it. Its market value was about $35.1bn (in US dollars) on 16/10/2026.
A fund’s weight in a company is the share of the fund’s money held in that company’s shares. A weight of 5% in a fund worth £1 billion is about £50 million. Index funds hold companies in proportion to their size in the index, so the largest companies appear in many funds at similar weights.
The list above comes from holdings the fund issuers publish, each dated, and names the funds where Royalty Pharma plc is one of the ten largest holdings — the part of every fund page open to anyone. Some issuers publish only their largest ten, so a fund can hold Royalty Pharma plc without it appearing in any list here. When two funds both hold the same large companies, owning both can be closer to owning one than it looks: the comparison page measures that overlap when both funds publish enough of their holdings.
Share price
- Latest price
- $60.96
- +2.25%on the day
- 52-week range
- $35.92–$64.38
- Price change, 1 year
- +68.7%
- Price change, this year
- +57.5%
- Market value
- $35.1bn
- Price to earnings (12 months)
- 32.5
Source: TradingView, as of , at least 15 min delayed